Bausch Health Companies (SWX:VRX) - Cotización, noticias y análisis

Resumen acción VRX

Bausch Health Companies Inc. opera como empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional.

Acerca de la empresa

VRX fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Cotiza un 92.1% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 64.46%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Patrimonio neto negativo

Competidores de Bausch Health Companies Inc.

Dottikon ES Holding

SWX:DESN

CHF3.2b

Sandoz Group

SWX:SDZ

CHF12.0b

Cosmo Pharmaceuticals

SWX:COPN

CHF1.1b

Newron Pharmaceuticals

SWX:NWRN

CHF138.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Bausch Health Companies
Historical stock prices
Current Share Price	US$24.11
52 Week High	US$0
52 Week Low	US$0
Beta	0.86
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	0%
5 Year Change	2.42%
Change since IPO	-81.27%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	VRX	CH Pharmaceuticals	Mercado CH
7D	0%	1.0%	-0.8%
1Y	0%	-10.5%	-2.2%

Rentabilidad vs. Industria: VRX superó al sector Swiss Pharmaceuticals , que obtuvo un rendimiento del -1.2% el año pasado.

Rentabilidad vs. Mercado: VRX superó al mercado Swiss, que obtuvo un rendimiento del -1.2% el año pasado.

Volatilidad de los precios

Is VRX's price volatile compared to industry and market?
VRX volatility
VRX Average Weekly Movement	0%
Pharmaceuticals Industry Average Movement	3.0%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	1.9%

Precio estable de las acciones: VRX no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de VRX en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. opera como una empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional. Desarrolla, fabrica y comercializa una gama de productos principalmente en gastroenterología, hepatología, neurología, dermatología, productos farmacéuticos internacionales, productos de venta libre (OTC), dispositivos médicos estéticos y salud ocular. La empresa opera a través de cinco segmentos: Salix, Internacional, Solta Medical, Diversified y Bausch + Lomb.

Resumen de fundamentos de Bausch Health Companies Inc.

¿Cómo se comparan los beneficios e ingresos de Bausch Health Companies con su capitalización de mercado?
Estadísticas fundamentales de VRX
Capitalización bursátil	CHF2.92b
Beneficios(TTM)	-CHF539.64m
Ingresos (TTM)	CHF7.98b

0.4x

Ratio precio-ventas (PS)

-5.4x

Ratio precio-beneficio (PE)

¿Está VRX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VRX
Ingresos	US$8.76b
Coste de los ingresos	US$2.56b
Beneficio bruto	US$6.20b
Otros gastos	US$6.79b
Beneficios	-US$592.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 02, 2024

Beneficios por acción (BPA)	-1.61
Margen bruto	70.78%
Margen de beneficio neto	-6.76%
Ratio deuda/patrimonio	-27,302.4%

¿Cómo se ha desempeñado VRX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción VRX

Recompensas

Análisis de riesgos

Competidores de Bausch Health Companies Inc.

SWX:DESN

CHF3.2b

SWX:SDZ

CHF12.0b

SWX:COPN

CHF1.1b

SWX:NWRN

CHF138.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Recent updates

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

New minor risk - Profitability

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold CHF681k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Second quarter 2022 earnings released

Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022

Insufficient new directors

Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insufficient new directors

Bausch Health Companies Inc. Announces Updates to Its Board of Directors

Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer

Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022

Bausch Health Companies Inc. Announces Management Changes

Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022

Bausch Health Companies Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2022

Bausch Health, Canada Announces Availability through Pharmacies Across Canada of its New Prescription Treatment TRULANCE

Bausch Health Companies Inc. to Report Q4, 2021 Results on Feb 23, 2022

Bausch Health Companies Inc. has filed an IPO.

Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection